FeesSafety
Pluang+

Bristol Myers Squibb offers growth and value in 2027, outperforming Novo Nordisk amid pricing pressures.

Market News
22 Nov 2026, 19:44 WIB
The Motley Fool
View Source
Bullish
Bristol Myers Squibb offers growth and value in 2027, outperforming Novo Nordisk amid pricing pressures.

Bristol Myers Squibb (BMY) and Novo Nordisk (NVO) are healthcare leaders with different strengths: BMY in oncology and hematology, and NVO in obesity and diabetes treatments. BMY shows steady revenue and net income growth for 2027, with a low valuation and strong pipeline despite risks from pricing pressures and patent expirations. Novo Nordisk leads in high-margin obesity drugs but faces pricing pressures and competition, with expected revenue and income declines in 2026 before long-term growth resumes. For 2027, BMY is favored for its growth and value balance.

Novo Nordisk trades at USD 37.82, down 2.70% as of Nov 23, 2026 01:01 WIB on Pluang, showing more volatility compared to Bristol Myers Squibb, which is up 0.84% at USD 58.83. Despite Novo Nordisk's larger market cap of $171.04B versus BMY's $120.19B, BMY offers a higher dividend yield of 4.29% compared to NVO's 4.75%. This trading activity complements the article's focus on the differing growth prospects and valuation between these healthcare giants.

More News (BMY)

Bristol Myers Squibb outgrows Novo Nordisk in 2027 with rising revenue and net income despite pricing pressures.

Bristol Myers Squibb outgrows Novo Nordisk in 2027 with rising revenue and net income despite pricing pressures.

Bristol Myers Squibb is expected to grow revenue by 3% and net income by over 40% in 2027, benefiting from new growth brands and a strong pipeline despite challenges like pricing pressures and patent expirations. Novo Nordisk, while dominant in obesi...

Market News
Bullish
27 minutes ago
Bristol Myers Squibb offers a 4.3% yield with strong new drug growth despite upcoming patent risks.

Bristol Myers Squibb offers a 4.3% yield with strong new drug growth despite upcoming patent risks.

Bristol Myers Squibb, a major pharmaceutical company, currently offers a 4.3% dividend yield and trades at a price-to-earnings ratio well below the industry average. Its newer drug portfolio generated nearly $7.7 billion in revenue last quarter, grow...

Market News
Bullish
1 day ago
Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.

Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.

Erasca has been upgraded from Hold to Buy following promising early trial results for its drug ERAS-0015, which showed unconfirmed response rates of 50% in pancreatic cancer and 64% in lung cancer. The company plans three registrational trials by 202...

Analyst Insights
Bullish
2 days ago
Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb increased its full-year 2026 earnings guidance following a 12% revenue growth in its growth portfolio to $7.7 billion, driven by eight medicines each generating over $1 billion annually. The company is offsetting losses from pate...

Company Fundamentals
Bullish
3 days ago
Bristol-Myers Squibb raises 2026 earnings guidance amid strong growth in new medicines.

Bristol-Myers Squibb raises 2026 earnings guidance amid strong growth in new medicines.

Bristol-Myers Squibb reported a 12% revenue increase in its growth portfolio to $7.7 billion for Q3 2026, driven by eight medicines each generating over $1 billion annually. The company advanced four late-stage clinical trials, including FDA clearanc...

Company Fundamentals
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App